OncologyLive asked experts in lymphoma, chronic myeloid leukemia, breast cancer, and non–small cell lung cancer to discuss the impact that the first targeted agents have had on these malignancies and the prospects for new therapeutic approaches.
By Anita T. Shaffer
Advertisement
Articles by By Anita T. Shaffer
The FDA's calendar for making decisions on new oncology drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes
Advertisement
Latest Updated Articles
Molecular Profiling Boosts Targeted Therapies in Phase I TrialPublished: June 4th 2011 | Updated:
13 Drugs to Watch in 2015Published: January 12th 2015 | Updated:
Moving Beyond Targeted Therapy Stalwarts: Experts Weigh In on Four Tumor TypesPublished: January 19th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5